Meihua Holdings Group Co.Ltd(600873) 3 on the evening of March 13, the annual report of 2021 was disclosed. During the reporting period, the company achieved an operating revenue of 22.837 billion yuan, an increase of 33.94% year-on-year; The net profit attributable to the parent company was 2.351 billion yuan, a record high, an increase of 139.40% over the previous year; The weighted average return on net assets was 26.32%, with a year-on-year increase of 15.33 percentage points. It is proposed to distribute a cash dividend of 4.0 yuan (including tax) to all shareholders for every 10 shares, and it is expected to distribute a cash dividend of about 1.239 billion yuan (including tax).
Meihua Holdings Group Co.Ltd(600873) said that in 2021, the company’s overall management and operation level entered a new development stage, and the cost advantages brought by the company’s multi product layout, scale and technology became more and more prominent. At the same time, Meihua Holdings Group Co.Ltd(600873) continuously promoted the standardized management of various production bases, procurement, sales and other business departments, adhered to the implementation of equity incentive plan, fully mobilized the enthusiasm and creativity of business backbone, and finally promoted the company’s annual budget objectives to be exceeded.
The annual report shows that the net cash flow from operating activities in Meihua Holdings Group Co.Ltd(600873) 2021 was 3.670 billion yuan, a year-on-year increase of 120.91%; The days of inventory turnover decreased from 54 days in 2020 to 51 days; The turnover days of accounts receivable decreased from 8 days in 2020 to 5 days. Continuous and efficient operation is also an important support for the improvement of Meihua Holdings Group Co.Ltd(600873) profitability.
In 2021, in the face of the rising prices of main raw materials in varying degrees, Meihua Holdings Group Co.Ltd(600873) seize the favorable opportunity to adjust the prices of main products by relying on the accurate analysis of market supply and demand, market share advantage and good customer relationship. During the reporting period, the sales price of lysine increased by 37.63% year-on-year, and the sales price of threonine increased by 44.75% year-on-year compared with 2020, which is one of the main profit growth points of the company.
Meihua Holdings Group Co.Ltd(600873) said that the company has made concerted efforts in both supply and marketing. In 2021, the company has always adhered to the “28” principle and continued to improve the proportion of the top 10 and top 20 customers in sales revenue in terms of sales customer management and new customer development. In order to more accurately formulate the sales strategy, we specially cooperate with external consulting companies to further build a standardized marketing system, reshape the whole sales team and improve its ability to undertake the company’s future strategy.
Meanwhile, Meihua Holdings Group Co.Ltd(600873) as the industry leader, actively responded to the national “double carbon” strategy and always adhered to the red line of safety, environmental protection and quality management in production, so as to achieve the goal of standardization, automation and intelligence of production management and the integration of supporting management of the whole industrial chain.
Due to the emphasis on talent training, the continuous implementation of employee stock ownership plan or equity incentive plan, the realization of long-term incentive mechanism for employees, and the combination of company development and personal development, the human efficiency ratio has increased year by year in recent years, ensuring the realization of the company’s strategic objectives.
Meihua Holdings Group Co.Ltd(600873) said that the company is a full chain synthetic biology company from genome editing to product landing, and has long been committed to the development and construction of synthetic biology technology platform. In 2021, more than 40 patents related to amino acid synthetic biology have been applied for. In the future, the company will continue to increase investment in basic research, strain R & D and application R & D, actively complete the layout of its own intellectual property rights, establish long-term cooperative relations with world-class synthetic biology scientists and scientific research institutions, and build a healthy R & D ecology. (Tian Limin)
